Obesity - orlistat (replaced by CG43)

Summary

This guidance is obsolete and has been replaced by CG43 Obesity.

Documents

For healthcare professionals

• TA22 Obesity - orlistat: Guidance (html)
• TA22 Obesity - orlistat: Guidance

For patients, carers and the public

• TA22 Obesity - orlistat: Information for the public
• TA22 Obesity - orlistat: Information for the public (html)

Background information

• Review of NICE Technology Appraisal Guidance Nos 22, orlistat and 31 sibutramine for the treatment of obesity in adults
• Orlistat for treatment of obesity in adults - HTA report
• 2001/010 - NICE issues guidance on Orlistat for obesity

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• None found